Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren Hodgson, J. Carl Barrett, Charlie Gourley et al.|British Journal of Cancer|2018Cited by 233
Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance settingBrian Dougherty, J. Carl Barrett, Zhongwu Lai et al.|Oncotarget|2017Cited by 99
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapyStuart Spencer, Juliane M. Jürgensmeier, Aurélien Pommier et al.|British Journal of Cancer|2013Cited by 32
Correlation of Lactate Dehydrogenase Isoenzyme Profile With Outcome in Patients With Advanced Colorectal Cancer Treated With Chemotherapy and Bevacizumab or Cediranib: Retrospective Analysis of the HORIZON I StudyJair Bar, Glenwood D. Goss, Stuart Spencer et al.|Clinical Colorectal Cancer|2013Cited by 29
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranibAurélien Pommier, Juliane M. Jürgensmeier, Robert A. Shaw et al.|British Journal of Cancer|2014Cited by 14